KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) EPS (Basic) (2016 - 2025)

Supernus Pharmaceuticals has reported EPS (Basic) over the past 15 years, most recently at -$0.07 for Q4 2025.

  • Quarterly EPS (Basic) fell 125.0% to -$0.07 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.68 through Dec 2025, down 150.75% year-over-year, with the annual reading at -$0.68 for FY2025, 150.75% down from the prior year.
  • EPS (Basic) was -$0.07 for Q4 2025 at Supernus Pharmaceuticals, up from -$0.8 in the prior quarter.
  • Over five years, EPS (Basic) peaked at $0.7 in Q3 2024 and troughed at -$0.8 in Q3 2025.
  • The 5-year median for EPS (Basic) is $0.13 (2022), against an average of $0.14.
  • Year-over-year, EPS (Basic) skyrocketed 1900.0% in 2024 and then crashed 8147.81% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at $0.05 in 2021, then soared by 840.0% to $0.47 in 2022, then plummeted by 95.74% to $0.02 in 2023, then skyrocketed by 1300.0% to $0.28 in 2024, then tumbled by 125.0% to -$0.07 in 2025.
  • Per Business Quant, the three most recent readings for SUPN's EPS (Basic) are -$0.07 (Q4 2025), -$0.8 (Q3 2025), and $0.4 (Q2 2025).